switching tirzepatide to semaglutide Why You Might Tolerate One Weight Loss Drug Better Than Another Transitioning Treatments: What to Expect

10.1007/s11033-022-07673-x 88 MeiB.LiH.ZhuJ.YangJ.YangZ.WenZ.et al (2017)

It is linked to elevated levels of fibrinogen and C-reactive protein, diabetes, insulin resistance, dyslipidemia, and hypertension, all of which raise the risk of CVD events ( It is less evident how GLP-1 agonists directly affect arrhythmias, some studies suggest they may reduce frequency of arrythmias because their favorable effects on metabolism and over all cardiovascular health

Volume status monitoring becomes critical

Its an FDA-approved, guideline-supported treatment for glycemic management, which puts it in a completely different category than weight-loss drugs that face blanket exclusions

P-31 NMR changes in Alzheimer's and Huntington's disease brain Neurology 1984